Shanton Hits Milestone: Phase 2b Refractory/Tophaceous Gout Study With SAP-001 Fully Enrolled

Shanton Pharma, a clinical-stage biotech firm focused on innovative treatments for patients suffering from refractory and tophaceous gout, has officially completed the enrollment for its Phase 2b clinical trial of the investigational drug SAP-001.

Shanton’s CEO Dr. Bing Li said, “Reaching full enrollment is an important milestone in our 6-month gout study as this sets the clock for topline data readout in Q1 2025. The study aims to show similar good efficacy and safety results that we saw in our Phase 1 and 2a studies in regular gout patients, but now in the more challenging target population of truly refractory patients that often have a more severe form of gout with limited treatment options.”

He further adds, “The challenge of this study was to just enroll patients that do not respond to a maximum tolerable dose of conventional Xanthine Oxidase Inhibitors such as allopurinol or febuxostat, which we have now accomplished through full enrollment of the Phase 2b study”.